How Analytical Advances Reshape Biologic Patent Strategy
On Sept. 18, the U.S. Food and Drug Administration published notice of a draft strategy document on interchangeable biosimilars. The document reports the agency's workshop observation that analytical data are more...To view the full article, register now.
Already a subscriber? Click here to view full article